Popular Trials
Radiation Therapy
IMRT for Brain Cancer
Recruiting1 award3 criteria
Albuquerque, New Mexico
"This trial is comparing a newer type of radiation therapy called intensity modulated radiation therapy (IMRT) to the standard whole brain radiation therapy for treating brain metastases. The study aims to see if IM
Monoclonal Antibodies
Trastuzumab Emtansine Safety for Cancer
Recruiting1 awardPhase 2
Duarte, California
This trial is for people who have been receiving treatment with either trastuzumab emtansine or a combination of it with other anti-cancer therapies, and who are still benefiting from the treatment. The purpose of the trial is to continue to monitor the safety of the treatment.
Kinase Inhibitor
LOXO-435 for Bladder Cancer
Recruiting1 awardPhase 1
Nashville, Tennessee
This trial is testing LOXO-435, a new drug, to see if it can help treat advanced cancers with a specific genetic change. It aims to block a gene that helps cancer cells grow. The study will check the drug's safety and effectiveness in these patients. LOX may be a potential effective therapeutic target to treat colorectal cancer.
Popular Filters
Trials for Breast Cancer Patients
Selective Estrogen Receptor Downregulator (SERD)
Imlunestrant + Abemaciclib for Breast Cancer
Recruiting2 awardsPhase 3
Chandler, Arizona
This trial is testing a new drug called imlunestrant, alone and in combination with another drug, abemaciclib, for patients with advanced breast cancer that is ER+ and HER2-. Imlunestrant works by blocking estrogen receptors on cancer cells, while abemaciclib stops the cells from multiplying. The goal is to see if these treatments work better than standard hormone therapy.
Estrogen Receptor Antagonist
Abemaciclib + Fulvestrant for Breast Cancer
Recruiting1 awardPhase 3
Phoenix, Arizona
This trial is testing a combination of two drugs, abemaciclib and fulvestrant, for treating a specific type of breast cancer that has not responded to previous treatments. Abemaciclib is taken orally and is approved for treating certain types of breast cancer. The goal is to see if this combination can help stop the cancer from growing. The study may last several years, depending on how well the treatment works for each patient.
Hormone Therapy
Vepdegestrant + PF-07220060 for Breast Cancer
Recruiting1 awardPhase 1 & 2
Fort Collins, Colorado
This trial is testing a new potential treatment for advanced metastatic breast cancer. Participants will receive two medications by mouth and will be monitored to see how safe and effective the treatment is. They will continue taking
Trials for LABC Patients
Selective Estrogen Receptor Downregulator (SERD)
Imlunestrant + Abemaciclib for Breast Cancer
Recruiting2 awardsPhase 3
Chandler, Arizona
This trial is testing a new drug called imlunestrant, alone and in combination with another drug, abemaciclib, for patients with advanced breast cancer that is ER+ and HER2-. Imlunestrant works by blocking estrogen receptors on cancer cells, while abemaciclib stops the cells from multiplying. The goal is to see if these treatments work better than standard hormone therapy.
Estrogen Receptor Antagonist
Abemaciclib + Fulvestrant for Breast Cancer
Recruiting1 awardPhase 3
Phoenix, Arizona
This trial is testing a combination of two drugs, abemaciclib and fulvestrant, for treating a specific type of breast cancer that has not responded to previous treatments. Abemaciclib is taken orally and is approved for treating certain types of breast cancer. The goal is to see if this combination can help stop the cancer from growing. The study may last several years, depending on how well the treatment works for each patient.
Hormone Therapy
Vepdegestrant + PF-07220060 for Breast Cancer
Recruiting1 awardPhase 1 & 2
Fort Collins, Colorado
This trial is testing a new potential treatment for advanced metastatic breast cancer. Participants will receive two medications by mouth and will be monitored to see how safe and effective the treatment is. They will continue taking
Trials for Metastatic Patients
Radiation Therapy
Laser Ablation + Radiosurgery for Spinal Cancer
Recruiting1 award
Detroit, Michigan
This trial is testing a new way to treat tumors near the spinal cord by combining two existing treatment methods. The goal is to improve tumor control and quality of life for patients with spinal metastasis.
Selective Estrogen Receptor Downregulator (SERD)
Imlunestrant + Abemaciclib for Breast Cancer
Recruiting2 awardsPhase 3
Chandler, Arizona
This trial is testing a new drug called imlunestrant, alone and in combination with another drug, abemaciclib, for patients with advanced breast cancer that is ER+ and HER2-. Imlunestrant works by blocking estrogen receptors on cancer cells, while abemaciclib stops the cells from multiplying. The goal is to see if these treatments work better than standard hormone therapy.
Small Molecule Inhibitor
BI 1810631 for Advanced Cancer
Recruiting1 awardPhase 1
Dallas, Texas
This trial is testing a new medicine called BI 1810631, which is taken as tablets. It targets adults with advanced cancers that have specific genetic changes and have not responded to other treatments. The goal is to find a safe dose and see if it can help shrink tumors.
Chemotherapy
EMB-01 for Advanced Cancer
Recruiting1 awardPhase 1 & 2
Boston, Massachusetts
This trial is testing a new medicine called EMB-01 in patients with advanced cancers who have no other treatment options. EMB-01 aims to block two proteins that help cancer cells grow, making it harder for the cancer to survive.
Trials for ER Positive Patients
Selective Estrogen Receptor Downregulator (SERD)
Imlunestrant + Abemaciclib for Breast Cancer
Recruiting2 awardsPhase 3
Chandler, Arizona
This trial is testing a new drug called imlunestrant, alone and in combination with another drug, abemaciclib, for patients with advanced breast cancer that is ER+ and HER2-. Imlunestrant works by blocking estrogen receptors on cancer cells, while abemaciclib stops the cells from multiplying. The goal is to see if these treatments work better than standard hormone therapy.
Hormone Therapy
Vepdegestrant + PF-07220060 for Breast Cancer
Recruiting1 awardPhase 1 & 2
Fort Collins, Colorado
This trial is testing a new potential treatment for advanced metastatic breast cancer. Participants will receive two medications by mouth and will be monitored to see how safe and effective the treatment is. They will continue taking
Trials for PR Positive Patients
Simvastatin + Anti-HER2 Therapy for Breast Cancer
Recruiting1 awardPhase 2
Houston, Texas
This trial tests if adding simvastatin, a cholesterol-lowering drug, to the current treatment can help patients with advanced breast cancer that has spread and is not responding to usual treatments. The goal is to see if this combination can make the cancer treatment work better. Simvastatin, originally used to lower cholesterol, has been studied since the 1990s for its potential anticancer effects, including in breast cancer.
FES PET/CT Imaging for Predicting Treatment Response in Breast Cancer
Recruiting1 awardPhase 2
Birmingham, Alabama
This trial will study using F-18 16 alpha-fluoroestradiol positron emission tomography/computed tomography to see if it can help predict response to endocrine therapy in patients with newly diagnosed breast cancer.
Chemotherapy
Olaparib for Metastatic Breast Cancer
Recruiting2 awardsPhase 3
San Diego, California
This trial will compare the effectiveness and safety of olaparib to standard chemotherapy in treating breast cancer that has spread to other parts of the body and has a mutation in the BRCA1 or BRCA2 gene.
Phase 3 Trials
Selective Estrogen Receptor Downregulator (SERD)
Imlunestrant + Abemaciclib for Breast Cancer
Recruiting2 awardsPhase 3
Chandler, Arizona
This trial is testing a new drug called imlunestrant, alone and in combination with another drug, abemaciclib, for patients with advanced breast cancer that is ER+ and HER2-. Imlunestrant works by blocking estrogen receptors on cancer cells, while abemaciclib stops the cells from multiplying. The goal is to see if these treatments work better than standard hormone therapy.
Monoclonal Antibodies
LY3537982 + Immunotherapy/Chemotherapy for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 3
Tucson, Arizona
This trial is testing a new drug, LY3537982, combined with standard treatments for patients with advanced lung cancer that have a specific genetic mutation. The goal is to see if this combination works better than the usual treatments alone.
Estrogen Receptor Antagonist
Abemaciclib + Fulvestrant for Breast Cancer
Recruiting1 awardPhase 3
Phoenix, Arizona
This trial is testing a combination of two drugs, abemaciclib and fulvestrant, for treating a specific type of breast cancer that has not responded to previous treatments. Abemaciclib is taken orally and is approved for treating certain types of breast cancer. The goal is to see if this combination can help stop the cancer from growing. The study may last several years, depending on how well the treatment works for each patient.
Chemotherapy
Olaparib for Metastatic Breast Cancer
Recruiting2 awardsPhase 3
San Diego, California
This trial will compare the effectiveness and safety of olaparib to standard chemotherapy in treating breast cancer that has spread to other parts of the body and has a mutation in the BRCA1 or BRCA2 gene.
Trials With No Placebo
Radiation Therapy
Laser Ablation + Radiosurgery for Spinal Cancer
Recruiting1 award
Detroit, Michigan
This trial is testing a new way to treat tumors near the spinal cord by combining two existing treatment methods. The goal is to improve tumor control and quality of life for patients with spinal metastasis.
Selective Estrogen Receptor Downregulator (SERD)
Imlunestrant + Abemaciclib for Breast Cancer
Recruiting2 awardsPhase 3
Chandler, Arizona
This trial is testing a new drug called imlunestrant, alone and in combination with another drug, abemaciclib, for patients with advanced breast cancer that is ER+ and HER2-. Imlunestrant works by blocking estrogen receptors on cancer cells, while abemaciclib stops the cells from multiplying. The goal is to see if these treatments work better than standard hormone therapy.
Small Molecule Inhibitor
BI 1810631 for Advanced Cancer
Recruiting1 awardPhase 1
Dallas, Texas
This trial is testing a new medicine called BI 1810631, which is taken as tablets. It targets adults with advanced cancers that have specific genetic changes and have not responded to other treatments. The goal is to find a safe dose and see if it can help shrink tumors.
Behavioural Intervention
Communication Intervention for Dementia
Recruiting1 award12 criteria
Seattle, Washington
This trial is testing whether or not the Jumpstart intervention can improve patient-centered outcomes for those with chronic illness. The study will specifically look at Alzheimer's disease and related dementias, but will also include other common chronic illnesses. The trial will assess the efficacy of the intervention by measuring quality of care, intensity of care outcomes, and patient- and family-reported outcomes. There will also be a mixed-methods evaluation of the implementation of the intervention to explore barriers and facilitators to future implementation and dissemination.
Chemotherapy
EMB-01 for Advanced Cancer
Recruiting1 awardPhase 1 & 2
Boston, Massachusetts
This trial is testing a new medicine called EMB-01 in patients with advanced cancers who have no other treatment options. EMB-01 aims to block two proteins that help cancer cells grow, making it harder for the cancer to survive.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.